Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
Author(s): Hagen F. Kennecke, MD, MHA1;Chris J. O’Callaghan, PhD, DVM, MSc2;Jonathan M. Loree, MD, MS3;Hussein Moloo, MD, MPH4;Rebecca Auer, MD, MSc4;Derek J. Jonker, MD4;Manoj Raval, MD, MSc5;Reilly Musselman, MD4;Grace Ma, MD6;Antonio Caycedo-Marulanda, MD6;Vlad V. Simianu, MD7;Sunil Patel, MD2;Lacey D. Pitre, MD8;Ramzi Helewa, MD, MSc9;Vallerie L. Gordon, MD10;Katerina Neumann, MSc, PhD, MD11;Halla Nimeiri, MD12;Max Sherry, MSc, MBA2;Dongsheng Tu, PhD2;and Carl J. Brown, MD, MSc5
Author Affiliations
1Providence Cancer Institute and Earle A Chiles Research Institute, Portland, OR;2Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;3BC Cancer, Vancouver, BC, Canada;4The Ottawa Hospital Research Institute, Ottawa, ON, Canada;5Providence-St. Paul’s Hospital, Vancouver, BC, Canada;6Health Sciences North, Sudbury, ON, Canada;7Virginia Mason Cancer Institute, Seattle, WA;8Juravinski Cancer Center, Hamilton, ON, Canada;9University of Manitoba, Winnipeg, MB, Canada;10CancerCare Manitoba, Winnipeg, MB, Canada;11Nova Scotia Health, Halifax, NS, Canada;12Foundation Medicine, Cambridge, MA